A PROSPECTIVE STUDY ON ORAL HYPOGLYCEMIC AGENTS (OHA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE

*Dr. Fatima Khatoon, Dr. Syed Mohammed Kazim, Dr. M. A. Aleem, Syeda Baseera Fatima, Tanaz Anjum, Omer Bin Amer, Sariya Fatima

ABSTRACT

Aim: To assess the oral hypoglycemic agents in patients with type 2 diabetes and cardiovascular disease.
Objectives
 To identify which hypoglycemic agents are safest for type2 diabetes and cardiovascular disease.
 To optimize oral hypoglycemic agents in type2 diabetes.
 To assess the effects of oral hypoglycemic agents on cardiovascular events.
 To reduce the symptoms and long-term complication of diabetes and cardiovascular disease.
Methodology: An observational study involving analysis of prescriptions of Type 2 diabetes diagnosed and treated for cardiovascular disease using patient data collection form and patient interview for a study period of 6 months. Results: This study examined the prevalence of cardiovascular diseases among type 2 DM in 110 Patients. Keeping it in view we monitored the glucose levels of all the patients and the results interpreted are the majority of the patients studied were over 41 years old and had Comorbidities such as Hypertension, Thyroid, CAD, CKD, AKI, UTI, CVA, Seizure’s and Asthma. The study revealed that HYPERTENSION and CAD were the most prevalent cardiovascular diseases in patients, while it was more common in Male & Elderly Patients. Lab investigations were also analyzed, including Blood pressure and Blood glucose levels. The most commonly used anti-diabetic drugs were METFORMIN and DAPAGLIFLOZIN and many patients were also taking medication for other conditions such as hypertension and CAD. Conclusion: In conclusion, our study reveals a significant correlation between the use of oral hypoglycemic agents and cardiac health in type 2 diabetes patients with cardiovascular diseases. Notably, Metformin emerged as a frontrunner, demonstrating a remarkably high positive impact on cardiac health.

Keywords: Type 2 Diabetes, Cardiovascular Diseases, Oral Hypoglycemic Agents, Metformin, Cardiac Health.